N/A
N=68
The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism
Atherosclerosis · Low-density Lipoproteins Aggregation Susceptibility · Low-density Lipoprotein Lipid Composition · Cardiovascular Diseases
Bottom Line
View on ClinicalTrials.gov: NCT04152291 ↗Enrolled (actual)
68
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: LDL Aggregation Susceptibility — 111.3; 113.1 Minutes
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Ethyl-Eicosapentaenoic Acid (E-EPA) (Dietary_supplement)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Wihuri Research Institute
- Primary completion
- Jun 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY LDL Aggregation Susceptibility |
111.3; 113.1 | — |
| PRIMARY Total Blood Triglycerides |
-14 | — |
| PRIMARY EPA Incorporation Into LDL |
0.075; 0.274 | — |
Summary
40-70 healthy volunteers of ages 18 to 65 participate in a E-EPA-diet where 3,9 grams of E-EPA is added to their normal diet and lifestyles for a month. Blood samples will be collected before the study and at weeks 1 and 4 and also, two weeks after finishing the diet. Main study focuses are LDL aggregation susceptibility, lipid composition and proteoglycan binding affinity. In addition, important plasma lipid metabolism enzymes and lipid mediated resolvins are measured as well as several baseline characteristics.
Eligibility Criteria
Inclusion Criteria
- Healthy normolipidemic
Exclusion Criteria
- Prescription of blood thinner medicine
- Circulating Low-density lipoprotein > 5mmol/l, Triglycerides >3mmol/l
- Chronic use of pain medication
- Fish allergy
- Pregnancy
- Breastfeeding
Data sourced from ClinicalTrials.gov (NCT04152291). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.